Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Short-term Investments (2020 - 2025)

Historic Short-term Investments for Silence Therapeutics (SLN) over the last 5 years, with Q3 2025 value amounting to $20.2 million.

  • Silence Therapeutics' Short-term Investments changed N/A to $20.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.2 million, marking a year-over-year change of. This contributed to the annual value of $26.0 million for FY2024, which is 2966.19% down from last year.
  • Silence Therapeutics' Short-term Investments amounted to $20.2 million in Q3 2025.
  • Over the past 5 years, Silence Therapeutics' Short-term Investments peaked at $72.4 million during Q2 2025, and registered a low of $20.2 million during Q3 2025.
  • Over the past 3 years, Silence Therapeutics' median Short-term Investments value was $37.0 million (recorded in 2023), while the average stood at $45.4 million.
  • Data for Silence Therapeutics' Short-term Investments shows a peak YoY increase of 2966.19% (in 2024) and a maximum YoY decrease of 2966.19% (in 2024) over the last 5 years.
  • Over the past 3 years, Silence Therapeutics' Short-term Investments (Quarter) stood at $37.0 million in 2023, then decreased by 29.66% to $26.0 million in 2024, then decreased by 22.47% to $20.2 million in 2025.
  • Its Short-term Investments was $20.2 million in Q3 2025, compared to $72.4 million in Q2 2025 and $71.6 million in Q1 2025.